Jeffrey J. Kirshner, MD
The nonsteroidal anti-inflammatory drug naproxen significantly decreases the incidence, severity, and duration of pegfilgrastim-induced bone pain in patients diagnosed with a nonmyeloid cancer, according to the results of a phase III study.
Kirshner JJ, Heckler CE, Janelsins MC, et al. Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base [published online ahead of print April 16, 2012]. J Clin Oncol. doi: 10.1200/JCO.2011.37.8364.
... to read the full story